A new study looking at the fourth-generation MitraClip system (Abbott Vascular) has demonstrated its ability to reduce mitral regurgitation (MR) to 2+ or less in 98% of patients after 30 days in findings that include an excellent safety profile and the lowest all-cause mortality rate.